We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SLP:NASDAQSimulations Plus, Inc. Analysis

Data as of 2026-09-01 - not real-time

$18.40

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

At $18.40, Simulations Plus, Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. With RSI at 62.6 the momentum picture is approaching overbought, alongside a bearish MACD signal. Price has been bracketed by support at $18.28 and resistance at $18.42.
The shares look overvalued, trading on 46.0 times earnings above a sector average of 30.4. Consensus targets land 6.2% below where the shares trade now. Revenue is growing at 7.5% on a 9.9% profit margin.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 2.7%, a beta of 0.97 and a maximum drawdown of 45.5%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.

Top Market Events

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG PR...SLP Shareholder Alert: Robbins LLP is Investigating Allegations that the Officers and Directors of Simulation Plus, Inc.Enid News & Eagle1monJohnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting .

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 16.32
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 46.0 versus sector average of 30.4
  • Trading above the 200-day average of 16.32

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 46.0 versus sector average of 30.4
  • Analyst targets imply -6.2% versus the current price
  • Price-to-book of 2.68

Key Metrics & Analysis

Financial Health

Revenue Growth7.50%
Profit Margin9.88%
P/E Ratio46.0
ROE6.17%
ROA5.48%
Debt/Equity0.35
P/B Ratio2.7
Op. Cash Flow$24.9M
Free Cash Flow$18.4M
Industry P/E30.4

Technical Analysis

TrendBullish
RSI62.6
Support$18.28
Resistance$18.42
MA 20$18.36
MA 50$18.30
MA 200$16.32
MACDBearish
VolumeStable
Fear & Greed Index94.79

Valuation

Fair Value$18.37
Target Price$17.25
Upside/Downside-6.25%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.97
Volatility2.71%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.